A study to evaluate Immune-related adverse events (irAEs) in patients with Anti-PD-1 for advanced Non-Small Cell Lung Cancer
Latest Information Update: 18 Oct 2019
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 18 Oct 2019 New trial record
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer